Healthy Extracts, Inc. (Nevada)

Company overview

• Business model: Platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals.
• Primary focus: Heart health, brain health, and immune support through proprietary and patented nutraceutical products.
• Recent event: Acquired Gummy USA (HE Gummy USA, Inc. subsidiary) in 2025, adding contract manufacturing and formulation capabilities; corporate restructuring around the Gummy USA acquisition resulted in Donald Swanson returning as CEO and majority owner.

Subsidiaries and acquisitions

• Bergamet NA, LLC (BergaMet) — nutraceuticals focused on heart and immune health.
• Ultimate Brain Nutrients, LLC (UBN) — nutraceuticals for brain health.
• HE Gummy USA, Inc. (Gummy USA / GUSA) — acquired in 2025; provides gel-pack delivery, contract manufacturing, and formulation services; integrated into the company’s manufacturing and delivery architecture.
• Leadership changes related to the GUSA transaction: Donald Swanson became CEO and Chairman; Kevin “Duke” Pitts became President and COO; Robert Madden remained CFO and Manager of GUSA after the initial transaction.

Products and technology

• Heart & Immune Health (BergaMet line)
  • Citrus Bergamot SuperFruit with 47% Bergamot Polyphenolic Fraction Gold (BPF Gold).
  • Brands/formulations: BergaMet Pro+, BergaMet Mega+O, BergaMet HERHEART, BergaMet Cholesterol Command, BergaMet SPORTSHEART.
  • Technology emphasizes high BPF potency to support heart and metabolic health.
• Brain Health (UBN line)
  • Four Brain Health products built on Fuel4Thought® (F4T®) formulations.
  • Products include UBN ACTIVATE, UBN RELIEF, Brain Activate – Gel, Brain Activate – ENERGY Gel.
  • Proprietary F4T ingredients include C8 MCTs, Neumentix spearmint extract, FloraGLO lutein-related components and other phytonutrients; three to four patent-pending formulations and two patents issued as noted in company materials.
  • UBN RELIEF targets migraine management; F4T formulations have been studied for brain energy and cognitive function.
• Gel-pack delivery platform
  • Exclusive U.S. and Canada licensing and manufacturing agreement with GelTeq Pty Ltd (GELS) for ingestible gel technology.
  • GELS platform is used to develop and manufacture gel-pack formats for Bergamot and UBN ingredients.
  • In-house gel-pack product lines launched: Brain Activate – Gel (no caffeine) and Brain Activate – ENERGY Gel.
  • Plans include a gut health gel-pack; the company holds exclusive rights in the U.S. and Canada for gel-based nutraceuticals.
• Gummy USA / GUSA platform
  • Provides contract manufacturing, formulation services, and access to the company’s platform for multi-channel distribution.
  • Certain GUSA-related patents and trademarks are licensed via an oral worldwide license with Donald Swanson; royalty terms include $0.05 per unit for specific items.

Intellectual property

• Patents
  • Filings and continuations related to prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone ester, and other ketogenic sources.
  • Compositions and methods covering ketogenic agents, micronutrients, and brain health formulations (Activate/BergaMet lines).
  • Issued U.S. Patent No. 10,500,182 (expires 2036).
• Trademarks
  • Ketonomics (service mark; registration approved 2014; active in commercial use).
  • Trademark filings to support the Brain Health platform (examples include PharmDose and SureDose, with USPTO activity noted).
• Licenses
  • Exclusive U.S./Canada license with GELS for gel technology (active, renewable annually).
  • Oral worldwide license with Donald Swanson for certain patents and trademarks related to the GUSA platform (specified royalty payments).

Markets and channels

• Geography: Primary market is the United States; potential future expansion to Canada and other regions.
• Channels
  • E-commerce and direct-to-consumer (company websites, subscriptions).
  • Major online retailers (Amazon; Walmart.com).
  • Care-platform partnerships (Fullscript) — access to healthcare professionals and patients via the Fullscript platform.
  • Retail partnerships (Natural Grocers stores nationwide).
  • Private label and influencer programs, including a private label arrangement for ACTIVATE and BergaMet lines.

Influencer program

• Whitney Johns serves as a key influencer with private label arrangements and ongoing collaboration, including advertising and support through her channels.

Manufacturing and capacity

• In-house manufacturing capacity through the HE Gummy USA platform: approximately 12 million to 15 million dosage units per month, depending on formulation complexity and scheduling.
• Gel-pack delivery system adds a manufacturing and formulation architecture for precision-formulated ingestibles.

Customers and go-to-market

• Bergamot products are listed on Amazon and Walmart.com.
• Fullscript provides access to healthcare professionals and patients for the company’s products.
• Natural Grocers carries BergaMet and UBN products.
• Gummy USA supports contract and private-label manufacturing relationships, including influencer-driven product lines.

Financial snapshot (as of December 31, 2025)

• Profitability: Not profitable to date; management has a plan to achieve profitability with new product introductions and cash flow improvements.
• Net loss (from inception through December 31, 2025): $20,121,462.
• Liquidity: Cash on hand as of December 31, 2025 — $146,935.
• Gross margin: Reported range of 60% to 70%, depending on product and channel.
• Outstanding securities
  • Total common stock outstanding: 16,870,868 shares.
  • Freely tradable shares: 1,705,640.
  • Company intends to register additional shares on Form S-8 for equity compensation.
• Ownership and control
  • Donald Swanson held a significant majority of common stock (over 75% at the referenced time), providing substantial influence over stockholder approvals and corporate matters.
  • Post-Gummy USA transaction: Swanson held 77.5% of issued and outstanding common stock after closing (subject to anti-dilution protections) and later returned to a CEO/board role.
• Going concern
  • Auditor notes indicate an ongoing need for additional financing; the company plans to seek capital to continue operations and pursue growth.

Corporate structure and facilities

• Headquarters: 7375 Commercial Way, Suite 125, Henderson, NV 89011.
• Other facilities (warehouses)
  • Henderson, NV: 7375 Commercial Way, 3,632 sq ft; lease Feb 2025 – Feb 2028; rent $6,677.
  • Northgate, Sarasota, FL: 4560 Northgate Court, 6,336 sq ft; lease Oct 1, 2023 – Sep 30, 2028; rent $10,579.
  • Whitfield, Sarasota, FL: 2340 Whitfield Park Ave, 3,000 sq ft; lease Feb 1, 2024 – month-to-month; rent $4,305.

Strategic summary

• Growth strategy centers on new product introductions and strategic acquisitions within the fragmented nutraceutical market, with emphasis on higher-margin product lines and a multi-channel distribution approach.
• The business depends on its licensing relationship with GelTeq for gel-delivery technology and on licensing arrangements tied to certain Swanson patents and trademarks.